Astellas Flashes Cash For Ogeda's Women's Health Drug
Astellas is spending €500m up front to acquire Belgium-based biotech Ogeda for its pipeline of women's health products, including Phase II drug candidate fezolinetant, a non-hormonal treatment for menopausal hot flashes that could be on the market within five years.
You may also be interested in...
Armed with a fresh injection of £25m, the UK's KaNDy is about to begin Phase IIb trials of a dual mechanism therapy it believes will be a transformational treatment to tackle two key symptoms of the menopause, hot flashes and night time awakenings.
Faster relief of debilitating menopausal symptoms in early-stage clinical trial results suggest a potential new class of products being evaluated by UK biotech KaNDy Therapeutics may be useful against the condition.
NeRRe Therapeutics has set up a new entity around a drug which it believes could be an effective alternative to hormone replacement therapy for hot flashes that may rapidly reduce debilitating sleep disturbance.